Somatic molecular changes and histo-pathological features of colorectal cancer in Tunisia

Table 2 Statistical analysis of clinicopathological parameters of the 51 colorectal cancer studied tumors as a function of tumoral phenotype n (%)

	Mutation MMR -	Mutation MMR +	Family history of colorectal cancer		P	Ams - and Beth -	Ams - and Beth +	P	Ams (- or +) and Beth +	P
	(n = 6)	(n = 4)	Yes (n = 8)	No (n = 43)		(n = 26)	(n = 22)		(n = 25)
Mutation geminale
MMR+			4	0		0	2		4
MMR-			3	3		0	5		6
Site of tumor (CCR)					NS			NS		NS
Right colon	1	3	5 (63)	10 (23)		5 (19)	9 (41)		10 (40)
Left colon	2	0	1 (13)	14 (33)		8 (31)	7 (32)		7 (28)
Rectum	3	1	2 (25)	19 (44)		13 (50)	6 (27)		8 (32)
Left colon + rectum	5	1	3 (38)	33 (77)	0.039	21 (81)	13 (59)	NS	15 (60)	NS
Right + left colon	3	3	6 (75)	24 (56)	NS	13 (50)	16 (73)	NS	17 (68)	NS
TNM Stage					NS			NS		NS
I	0	1	1 (14)	2 (5)		2 (8)	0 (0)		1 (4)
II	1	0	2 (29)	23 (53)		16 (62)	9 (41)		9 (38)
III	4	3	4 (57)	15 (35)		7 (27)	11 (50)		12 (50)
IV	0	0	0 (0)	3 (7)		1 (4)	2 (9)		2 (8)
I/II	1	1	3 (43)	25 (58)	NS	18 (69)	9 (41)		10 (42)
III/IV	4	3	4 (57)	18 (42)		8 (31)	13 (59)	NS	14 (58)	0.050
Microsatellite instability					< 0.001			NS		0.038
MSI (MSI-L or MSI-H)	1	4	6 (75)	4 (9)		2 (8)	6 (27)		8 (32)
MSS (MSI-L or MSS)	5	0	2 (25)	39 (91)		24 (92)	16 (73)		17 (68)
Somatic mutations
TP53	6	0	3 (38)	25 (64)	NS	14 (61)	13 (62)	NS	14 (58)	NS
KRAS	1	2	2 (25)	14 (33)	NS	9 (35)	5 (23)	NS	7 (28)
BRAF	0	0	0 (0)	1 (2)		1 (4)	0 (5)		0 (0)
CTNNB1	0	0	0 (0)	1 (2)		0 (0)	1 (5)		1 (4)
Immunohistochemistry
Loss of MMR	1	4	5 (50)	5 (50)	NS	2 (8)	6 (27)	NS	8 (32)	0.038
Overexpression of p53	5	0	2 (25)	19 (44)	NS	9 (35)	11 (50)	NS	12 (48)	NS
Overexpression of MUC5AC	2	3	5 (63)	10 (23)	0.039	6 (23)	8 (36)	NS	9 (36)	NS

Ams: Extented Amsterdam II criteria; NS: Not statistically significant; Beth: Revised Bethesda Guidelines; MMR: Mismatch repair; CCR: Colorectal cancer; MSI: Microsatellite instability; MSS: Microsatellite stable; MUC: Mucin.